AzTrials
AzTrials

Postoperative PainPhase 2/3NCT03730714

Surgicel and Analgesic Reservoir

A Phase 2/3 study testing "Local Anesthetic", "Epinephrine" and "Morphine", "Local Anesthetic", "Epinephrine", "Morphine" and "Surgicel" and "Normal Saline" in people with Postoperative Pain, run by Assiut University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Laparoscopic cholecystectomy (LC) is a widespread surgical procedure with superior outcomes in terms of the incurred postoperative pain, recovery time, cosmetic, and morbidity issues. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Postoperative Pain
What is being tested?
"Local Anesthetic", "Epinephrine" and "Morphine", "Local Anesthetic", "Epinephrine", "Morphine" and "Surgicel" and "Normal Saline"
Could I receive a placebo?
No, everyone receives an active treatment
How many people
90 participants
Where
1 siteEgypt
Study dates
15 Nov 2018to 12 Aug 2020
Phase
Phase 2/3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age 18-65 years old patients from both genders scheduled for laparoscopic cholecystectomy
  • Clinical and laboratory multisystem preoperative evaluation prove a health status of American society of Anesthesiology grade I/II
  • Absence of current active inflammatory medical condition

Who cannot join

  • Allergic reaction to the study medicine
  • Patients' health status beyond the specified range
  • Patients with seizure diseases
  • Patients with significant chronic respiratory disease
  • Patients with intraperitoneal infection

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Assiut University Hospitals

    Asyut, 71515

Other trials in Egypt

About this study

Official title: Surgicel; a Probable Analgesic Reservoir for Post-laparoscopic Cholecystectomy Pain Management; Randomized Controlled Double-blind Trial

Laparoscopic cholecystectomy (LC) is a widespread surgical procedure with superior outcomes in terms of the incurred postoperative pain, recovery time, cosmetic, and morbidity issues. Although it is associated with less postoperative pain compared to open cholecystectomy, but patients still experience significant pain. Pain after LC is categorized into three types: referred pain to the right shoulder due to diaphragmatic stretching during gas insufflation; visceral pain due to dissection and injury at the hepatic fossa during gall bladder removal; and somatic pain due to tissue injury at the port sites. Since the discovery of LC in 1987 by a French surgeon, Phillipe Mouret, it became the gold standard for surgical excision of the gallbladder. Local anesthetics (LA) has been tried for analgesia after LC in variable techniques and concentrations. It was proved to be a safe and valid method for reducing pain after LC instilled intraperitoneal and infiltrated at the port sites.

Surgicel is an absorbable gelatin sponge that is non-toxic, non-allergenic, non-immunogenic, and non-pyrogenic. It is gamma-sterilized and provided with double packing. The sponge is easily cut to fit the surgical cavity. It may be applied dry to the wound. It absorbs 40 times its weight of whole blood or 50 times of water and adheres easily to the bleeding site. It forms a stable adherent coagulum. When implanted in vivo, it is completely absorbed within 3-5 weeks. The rationale for using this sponge as interposition material is to act as a carrier for the analgesic drugs and allow for its local sustained release, and for local hemostasis. Bupivacaine will be used as the main local anesthetic medication in the study. It provides variable pain relief when either used to irrigate intraperitoneal space as a sole analgesic or combined with opioids. Lidocaine 2% will be mixed with bupivacaine to expedite the onset of analgesia. Epinephrine will be used as 5 microgram/ml of the total mixture of used fluids in order to prolong the time of action of the block.

Read the detailed description

Eligibility and type of the study: This prospective randomized placebo-controlled double-blind study will be conducted after approval from the Institutional Ethics Committee and obtaining a written informed consent from patients undergoing elective laparoscopic cholecystectomy under general anesthesia.

Sample Size: Sample size was calculated according to the previously conducted similar studies in the same field. Based on a pilot study, where the incidence of postoperative pain after laparoscopies was found to be more than 70% and intervention that can cause 50% reduction in this incidence was required. With a power of 90% and type I error of 5%, 26 patients were required to be in each group but to avoid possible patients dropouts, the number of patients in each group is increased to 30 (total of 90 patients).

Drugs Coding and Randomization: Patients will be randomly allocated into three equal groups (30 patients each) using a computer-generated table of random numbers in order to allocate the patients into the three study groups. Neither the anesthesia provider nor the participant will be aware of the study group or the drug used. One anesthesiologist (not included in the procedure, observation or in the data collection) will prepare the study drugs. Two surgeons with average similar level of experience in the field will operate upon patients sequentially without a specific order. All patients will have full explanation about the anesthetic and analgesic techniques they will have before signing their consent.

Anesthesia Technique:

  • Before the day of the surgery, patients will visit the outpatient clinic for medical assessment and description of the study protocol after securing their eligibility to participate in the study. Laboratory investigations will be performed and patients will sign the consent. All patients will receive the standard general anesthesia technique followed in the hospital: preoperative 8 hours of NPO, premedication with proton pump inhibitor and antiemetic.
  • At operative theatre, patients will be connected to five standard monitoring measures: electrocardiography (ECG), non-invasive blood pressure (NIBP), pulse oxymetry (SpO2), core body temperature, and end-tidal carbon dioxide. An intravenous cannula 18G will be inserted in the dorsum of the non-dominant hand and normal saline 0.9% IV fluids will be infused at a rate of (6-8 ml/kg/h) throughout the surgery.
  • After 3 minutes of pre-oxygenation with 100% O2 via the appropriate size face mask, general anesthesia will be induced with 1 µg/kg of fentanyl, 2-3 mg/kg of propofol, cisatracurium (0.15 mg/kg). Patients will be intubated with an appropriate size cuffed endotracheal tube under direct laryngoscopy after complete muscular relaxation. Anesthesia will be maintained with sevoflurane at 2-3% MAC and cisatracurium 0.03 mg/kg. Mechanical ventilation will be maintained and respiratory parameters will be adjusted to keep the end-tidal CO2 at 35-45 mmHg. At the end of the surgery, residual neuromuscular blockade will be pharmacologically reversed using neostigmine 0.04 mg/kg and atropine 0.02 mg/kg, and trachea will be extubated once the patient is showing clinical signs of clearance from neuromuscular blockade and TOF ratio of 0.9 is achieved. In order to control postoperative pain; the patients will receive I.V. paracetamol 1 gm (Perfalgan, Paracetamol 1000 mg. UPSA laboratories, France).

The Study Technique:

After the end of the operative procedure, the patient will have a cut piece of surgicel folded, passed through the big port and intersected dry to cover the gallbladder bed area of the hepatic fossa. The prepared study mixture of medicine will be 32 ml:

  • Instilled to soak the surgicel at the hepatic fossa (10 ml).
  • Splash the undersurface of the right copula of the diaphragm (10 ml).
  • Instilled to soak small pieces of surgicel intersected in the port areas (12 ml).

Groups:

  1. First study group (LAM) will receive local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg) instilled into the assigned areas according to the technique.
  2. Second study group (LAMG) will receive the same mixture in LAM-group to soak the surgicel according to the previous planned technique
  3. Control group (CG) will receive normal saline 0.9% to soak the surgicel according to the planned technique

Statistical Analysis:

Data will be collected and analyzed by computer program SPSS (SPSS Inc., Chicago, Illinos, USA) version 23. Data will be expressed as means, standard deviations, ranges, numbers and percentages. The analysis of variance and Chi-square test will be used to assess that the study groups are matched in terms of demographic data. Chi-Square or Fisher exact test will be used to determine significance for categorical variables. T-test or Mann-Whitney test if necessary will be used to determine significance for numeric variables. Kruskal-Wallis test followed by the Wilcoxon matched pairs rank test; will be used specifically to compare VAS and VRS. P value <0.05 will be considered statistically significant.

Being tested
"Local Anesthetic", "Epinephrine" and "Morphine", "Local Anesthetic", "Epinephrine", "Morphine" and "Surgicel", "Normal Saline"
Medical subject headings
Pain, Postoperative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • "Local Anesthetic", "Epinephrine" and "Morphine"Drug

    local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)

  • "Local Anesthetic", "Epinephrine", "Morphine" and "Surgicel"Drug

    Surgicel soaked with mixture of: local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)

  • "Normal Saline"Drug

    normal saline 0.9% to soak the surgicel according to the planned technique

Study groups in NCT03730714
Study groupRoleWhat they receive
Ggroup LAMActive comparatorPatients will receive local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg) instilled into the assigned areas according to the technique.
Receives: Drug: "Local Anesthetic", "Epinephrine" and "Morphine"
Ggroup LAMGActive comparatorPatients will receive the same mixture in LAM-group to soak the surgicel according to the previous planned technique.
Receives: Drug: "Local Anesthetic", "Epinephrine", "Morphine" and "Surgicel"
Group CGActive comparatorPatients will receive normal saline 0.9% to soak the surgicel according to the planned technique.
Receives: Drug: "Normal Saline"

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Visual Analouge Scale

    Postoperative abdominal and shoulder pain using 0-10 scale (with 0 indicating no pain and 10 as the most severe pain ever experienced)

    Measured: 24 hours

Secondary outcomes (3)
  1. Peak expiratory flow rate

    by peak flow meter; a portable, inexpensive, hand-held device used to measure how air flows from the lungs in one fast blast.

    Measured: 60 minutes

  2. Postoperative Complications

    Percentages of patients with any postoperative complications will be recorded and treated promptly.

    Measured: 24 hours

  3. 5-point Likert scale

    Patient satisfaction score: (1= very satisfied, 2 = satisfied, 3 = neither satisfied nor dissatisfied, 4 = dissatisfied, 5 = very dissatisfied).

    Measured: 24 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Nov 2018
  2. Study start15 Nov 2018
  3. Primary completion12 Aug 2020
  4. Study completion12 Aug 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
90 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03730714
Sponsor's protocol ID
Surgicel
Status last verified
Aug 2020
First submitted
2 Nov 2018
Last updated
18 Aug 2020
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing "Local Anesthetic", "Epinephrine" and "Morphine", "Local Anesthetic", "Epinephrine", "Morphine" and "Surgicel" and "Normal Saline" in people with Postoperative Pain, run by Assiut University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Visual Analouge Scale (time frame: 24 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in